Key clinical point: Adding cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to endocrine therapy (ET) improved survival outcomes in elderly patients aged ≥65 years with advanced estrogen receptor-positive (ER+) breast cancer (BC).
Major finding: Adding CDK4/6 inhibitors to ET (letrozole or fulvestrant) significantly reduced the mortality risk by 21% (hazard ratio [HR] 0.79; 95% CI 0.69-0.91) and progression risk by 41% (HR 0.59; 95% CI 0.51-0.69) in older patients aged >65 years with BC.
Study details: Findings are from a meta-analysis of 10 trials including 1985 older patients with advanced ER+ BC who received ET with or without CDK4/6 inhibitors.
Disclosures: This study did not report the source of funding. The authors did not declare any conflicts of interest.
Source: Petrelli F et al. The role of CDK4/6 inhibitors in older and younger patients with breast cancer: A systematic review and meta-analysis. Breast. 2023 (May 12). doi: 10.1016/j.breast.2023.05.002